|By Marketwired .||
|June 23, 2014 03:00 AM EDT||
OKLAHOMA CITY, OK -- (Marketwired) -- 06/23/14 -- Cytovance Biologics, a leading full-service contract manufacturer of mammalian and microbial biologics, announces successful completion of GMP manufacture of ARMO BioSciences' lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-IL-10).
"Cytovance is proud to have been an integral partner in the manufacture of AM0010 bulk drug substance and drug product," states Darren Head, President and Chief Executive Officer of Cytovance Biologics. "Our team responded to the urgency to get this important drug to patients with advanced solid tumors."
"Cytovance's responsive and professional team enabled us to accelerate the time to clinic of AM0010 which is currently in a Phase 1 dose escalation study in patients with cancer," said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO. "We look forward to continuing our relationship with Cytovance as the manufacturer of product in support of the clinical development of AM0010."
"Cytovance's state-of-the-art facilities and staff are prepared to deliver the highest quality of manufacturing services for ARMO," adds Darren Head. "We are delighted to work with ARMO. Their fast pace and rigorous scientific know-how are a good match for Cytovance's sense of urgency and flexibility. Together, we can produce high quality material for patients quickly and efficiently in a cost-efficient manner."
About ARMO BioSciences, Inc.
ARMO BioSciences, a clinical stage biotechnology company based in Redwood City, CA is focused on developing immunotherapies for the treatment of cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases. ARMO believes that by harnessing the body's own capability to arm itself against dysregulated cells, it may provide safer and more effective drugs for patients suffering from grievous diseases. ARMO's medicines are designed to normalize the underlying biology of disease through immunotherapeutic mechanisms for sustained and durable responses. Founded in 2012, ARMO is backed by investors Kleiner Perkins Caufield & Byers, OrbiMed, DAG Ventures and NanoDimension.
Further information regarding ARMO BioSciences, Inc. is available at www.armobio.com.
About Cytovance® Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Learn more about Cytovance Biologics at www.cytovance.com.
Dec. 2, 2016 01:00 PM EST Reads: 1,367
Dec. 2, 2016 01:00 PM EST Reads: 2,434
Dec. 2, 2016 12:11 PM EST Reads: 132
Dec. 2, 2016 12:00 PM EST Reads: 1,823
Dec. 2, 2016 12:00 PM EST Reads: 121
Dec. 2, 2016 11:45 AM EST Reads: 1,450
Dec. 2, 2016 11:30 AM EST Reads: 1,842
Dec. 2, 2016 11:30 AM EST Reads: 3,737
Dec. 2, 2016 11:00 AM EST Reads: 392
Dec. 2, 2016 11:00 AM EST Reads: 393
Dec. 2, 2016 10:45 AM EST Reads: 1,590
Dec. 2, 2016 10:30 AM EST Reads: 1,897
Dec. 2, 2016 10:15 AM EST Reads: 2,020
As ridesharing competitors and enhanced services increase, notable changes are occurring in the transportation model. Despite the cost-effective means and flexibility of ridesharing, both drivers and users will need to be aware of the connected environment and how it will impact the ridesharing experience. In his session at @ThingsExpo, Timothy Evavold, Executive Director Automotive at Covisint, discussed key challenges and solutions to powering a ride sharing and/or multimodal model in the age ...
Dec. 2, 2016 10:00 AM EST Reads: 1,069
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, will discuss how AI can simplify cloud operations. He will cover the following topics: why clou...
Dec. 2, 2016 10:00 AM EST Reads: 502